Human IL-2 Receptor alpha enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.01 pg/ml (50 μl)；1.14 pg/ml (10 μl)； |
| Standard Curve Range | 1.37~1000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0082 | 0.0086 | 0.0084 | |
| 1.37 | 0.0274 | 0.0256 | 0.0265 | 0.0181 |
| 4.12 | 0.0649 | 0.0683 | 0.0666 | 0.0582 |
| 12.35 | 0.1922 | 0.1804 | 0.1863 | 0.1779 |
| 37.04 | 0.4898 | 0.4806 | 0.4852 | 0.4768 |
| 111.11 | 1.2600 | 1.1500 | 1.2050 | 1.1966 |
| 333.33 | 2.4250 | 2.4020 | 2.4135 | 2.4051 |
| 1000.00 | 3.6340 | 3.6390 | 3.6365 | 3.6281 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 19.2 | 115.7 | 350.8 | 18.1 | 103.6 | 361.9 |
| Standard Deviation | 0.9 | 5.4 | 18.3 | 0.7 | 4.9 | 14.8 |
| Coefficient of Variation(%) | 4.7 | 4.7 | 5.2 | 3.9 | 4.7 | 4.1 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human IL-2 Receptor alpha into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 89% to 118% with an overall mean recovery of 106%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 722.90-1772.29 | 100 | 1340.94 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-2 Receptor alpha in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: IL-2 Receptor alpha
Two type1 membrane proteins belonging to the hemopoietin receptor family have been cloned and shown to bind IL-13 with differing affinities. The lower affinity IL-13 binding protein, previously designated IL-13 R alpha, IL-13 R alpha l or NR4, is now referred to as IL-13 R alpha 1. The high affinity IL-13 binding protein, previously also designated IL-13 R or IL-13 R alpha l, is now referred to as IL-13 R alpha 2. Human IL-13 R alpha 2 was originally cloned from the Caki-1 human renal carcinoma cell line. The IL-13 R alpha 2 cDNA encodes a 380 amino acid (aa) residue precursor protein with a putative 26 aa residue signal peptide, a 317 residue extracellular domain, a 20 aa residue transmembrane region and a 17 aa residue cytoplasmic tail. Human and mouse IL‑13 R alpha 2 share 59% aa sequence identity. The extracellular domain of IL-13 R alpha 2 is also closely related to that of IL-13 R alpha 1. However, the 17 aa residue cytoplasmic domain of IL-13 R alpha 2 is much shorter than that of IL-13 R alpha 1, suggesting that the two receptors are functionally distinct. IL-13 R alpha 1 has been shown to combine with the IL-4 R to form a high-affinity receptor complex capable of transducing an IL‑13‑dependent proliferative signal. The role of IL-13 R alpha 2 in IL-13 signaling remains to be elucidated. The amino-terminal 27 aa residues of the human and mouse IL‑13 R alpha 2 are nearly identical to that of a soluble mouse IL-13 binding protein purified from mouse serum and urine.
